AP30663 achieved proof of mechanism with first-in-class SK channel inhibition compound in atrial fibrillation – primary endpoint met: 99.9% probability of superiority over placebo AP31969, a novel compound being developed for sinus rhythm maintenance in atrial fibrillation, commences dosing in phase 1 Copenhagen, Denmark, 13 December 2023 – Acesion Pharma (“Acesion” or “the Company”), a […]